EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bispecific antibodies and CAR T cells targeting a TP53 mutation–associated neoantigen show discordant affinity requirements

Sarah R DiNapoli, Katharine M Wright, Brian J Mog, Alexander H Pearlman, Tushar D Nichakawade, Nikita Marcou, Emily Han-Chung Hsiue, Michael S Hwang, Jacqueline Douglass, Qiang Liu, Evangeline Watson, Marco Dal Molin und 18 weitere

Journal of Clinical Investigation · 2026

DOI: 10.1172/jci192885 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Sarah R DiNapoli und 29 weiteren Autor:innen. Beteiligte Einrichtung: Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Tumor Suppressor Protein p53, Antigens, Neoplasm, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, NIAMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mutation-associated neoantigens (MANAs) are highly cancer-specific targets for immunotherapy where peptides derived from intracellular mutant proteins are presented on the cell surface via HLA molecules. T cell–engaging bispecific antibodies and CAR T cells can target MANAs to eliminate cancer cells via T cell activation. However, the low antigen density of MANAs on the cell surface can limit therapeutic efficacy. Here, we investigated whether increasing the affinity of the H2 single-chain variable fragment (scFv) targeting the p53 R175H MANA (HMTEVVRHC presented on HLA-A*02:01) improves its therapeutic effect. We identified higher-affinity H2 variants via phage biopanning and a thiocyanate elution method. Increasing bispecific antibody affinity to the low nanomolar range increased cancer cell killing and tumor control in mouse xenograft models without sacrificing antigen specificity. We next asked how increasing scFv affinity impacts CAR T cell function — a matter of debate. We appended each variant scFv to a CD28z CAR, CD3γ, or the T cell receptor. In striking contrast to the bispecific antibody results, increasing CAR affinity decreased function in each CAR format due to lower T cell activation upon interaction with target cancer cells. These results have important implications for the design of future immunotherapeutic approaches targeting low-density antigens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificTumor Suppressor Protein p53Antigens, NeoplasmReceptors, Chimeric AntigenImmunotherapy, AdoptiveSingle-Chain AntibodiesMutationT-LymphocytesHumansAnimalsMiceHLA-A2 AntigenXenograft Model Antitumor AssaysCell Line, TumorFemale

Stichwörter der Autor:innen

Cancer immunotherapyImmunologyImmunotherapyOncologyT cells

Substanzen

Antibodies, BispecificTumor Suppressor Protein p53Antigens, NeoplasmReceptors, Chimeric AntigenHLA-A2 AntigenTP53 protein, humanSingle-Chain AntibodiesHLA-A*02:01 antigen

Autor:innen und Institutionen

  • Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Howard Hughes Medical Institute, Chevy Chase, Maryland, USA.
  • Lustgarten Pancreatic Cancer Research Laboratory and.
  • Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Biomedical Engineering.

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS
  • NIAMS NIH HHS
  • NHLBI NIH HHS
  • NIH Cancer Center
  • National Cancer Institute
  • National Institute of General Medical Sciences
  • National Institutes of Health

Zitieren

APA

DiNapoli, S. R., Wright, K. M., Mog, B. J., Pearlman, A. H., Nichakawade, T. D., Marcou, N., Hsiue, E. H., Hwang, M. S., Douglass, J., Liu, Q., Watson, E., Dal Molin, M., Cohen, J. D., Popoli, M., Paul, S., Konig, M. F., Wyhs, N., Azurmendi, P. A., Glavaris, S., …, & Vogelstein, B. (2026). Bispecific antibodies and CAR T cells targeting a TP53 mutation–associated neoantigen show discordant affinity requirements. Journal of Clinical Investigation. https://doi.org/10.1172/jci192885

Vancouver

DiNapoli SR, Wright KM, Mog BJ, Pearlman AH, Nichakawade TD, Marcou N, et al. Bispecific antibodies and CAR T cells targeting a TP53 mutation–associated neoantigen show discordant affinity requirements. Journal of Clinical Investigation. 2026. doi:10.1172/jci192885

BibTeX
@article{DiNapoli2026,
  author = {DiNapoli, Sarah R and Wright, Katharine M and Mog, Brian J and Pearlman, Alexander H and Nichakawade, Tushar D and Marcou, Nikita and Hsiue, Emily Han-Chung and Hwang, Michael S and Douglass, Jacqueline and Liu, Qiang and Watson, Evangeline and Dal Molin, Marco and Cohen, Joshua D and Popoli, Maria and Paul, Suman and Konig, Maximilian F and Wyhs, Nicolas and Azurmendi, P Aitana and Glavaris, Stephanie and Ge, Jiaxin and Awosika, Tolulope O and Liu, Jin and Gabrielson, Kathleen L and Gabelli, Sandra B and Pardoll, Drew M and Bettegowda, Chetan and Papadopoulos, Nickolas and Kinzler, Kenneth W and Zhou, Shibin and Vogelstein, Bert},
  title = {Bispecific antibodies and CAR T cells targeting a TP53 mutation–associated neoantigen show discordant affinity requirements},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  doi = {10.1172/jci192885}
}
Kostenlos starten →